Cases & Deals

Astellas returns rights to Eligard® in Europe, Middle East, CIS, and Asia to Tolmar

Clients Astellas Pharma Inc.

Jones Day represented Astellas Pharma Europe Ltd. in connection with a series of transactions, including the sale of related assets, in which Astellas returned its in-licensing rights to Eligard® (leuprorelin acetate for injectable suspension), a treatment for advanced prostate cancer, sold by Astellas in Europe, the Middle East, the Commonwealth of Independent States (CIS) and Asia, to Tolmar International Limited. Tolmar concurrently licensed the rights to commercialize Eligard® in Europe, Turkey, Russia and other territories to Recordati Industria Chimica e Farmaceutica S.p.A. As a result of the transactions, Recordati is taking over the Astellas position as Eligard® licensee in these territories.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.